Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Shares Outstanding (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Shares Outstanding for 8 consecutive years, with $64.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 159.2% to $64.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.6 million through Dec 2025, up 159.2% year-over-year, with the annual reading at $53.9 million for FY2025, N/A changed from the prior year.
  • Shares Outstanding for Q4 2025 was $64.6 million at Outlook Therapeutics, up from $53.9 million in the prior quarter.
  • The five-year high for Shares Outstanding was $64.6 million in Q4 2025, with the low at $24.9 million in Q4 2024.